<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>RedChip Upcoming Webinars</title>
    <link>https://www.redchip.com/webinar</link>
    <atom:link href="https://www.redchip.com/webinar/rss" rel="self" type="application/xml" />
    <description>Latest upcoming webinars from RedChip.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 10 Dec 2026 14:30:00 +0000</lastBuildDate>
    <ttl>15</ttl>
    <item>
      <title><![CDATA[60 Degrees Pharmaceuticals]]></title>
      <link>https://www.redchip.com/webinar/SXTP/83874994795</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/SXTP/83874994795</guid>
      <pubDate>Tue, 10 Nov 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[FibroBiologics (NASDAQ: FBLG)]]></title>
      <link>https://www.redchip.com/webinar/FBLG/81516024226</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/FBLG/81516024226</guid>
      <pubDate>Thu, 19 Nov 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[FibroBiologics is a clinical-stage biotechnology company developing allogeneic, fibroblast-based cell therapies to address chronic diseases with large unmet needs. Its novel approach leverages the regenerative, immunomodulatory, and scalable properties of fibroblasts—offering a practical alternative to stem cell therapies. The company’s lead program, CYWC628, targets diabetic foot ulcers and is expected to enter a Phase 1/2 clinical trial in Australia in 2025. Additional candidates include CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis. Backed by over 270+ patents and a growing body of supportive preclinical data, FibroBiologics is advancing a platform with broad therapeutic potential across wound healing, neurodegeneration, and autoimmune conditions. With experienced leadership, strong IP, and near-term clinical catalysts, FibroBiologics offers investors early access to a differentiated, scalable cell therapy platform poised to disrupt multi-billion-dollar markets.]]></description>
    </item>
    <item>
      <title><![CDATA[Gunnison Copper (NYSE American: GUNN)]]></title>
      <link>https://www.redchip.com/webinar/GUNN/85774716182</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/GUNN/85774716182</guid>
      <pubDate>Mon, 23 Nov 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[Gunnison Copper Corp. is a pure-play U.S. copper company focused on producing and developing refined copper in Southern Arizona. The Company operates the Johnson Camp Mine, one of America’s newest copper producers, which reached commercial production in September 2026 and is ramping toward nameplate capacity of up to 25 million pounds of copper annually. Johnson Camp produces 99.999% pure copper cathode on site from Arizona mineralized material, eliminating the need for offshore smelting or refining, and its copper is entering supply chains serving U.S. defense and data-center infrastructure. The approximately US$200 million mine restart was fully funded by Nuton, a Rio Tinto venture, and was permitted in under 12 months and advanced from final investment decision to first production in under 18 months.]]></description>
    </item>
    <item>
      <title><![CDATA[Venu Holding Corporation (NYSE American: VENU)]]></title>
      <link>https://www.redchip.com/webinar/VENU/87964071692</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/VENU/87964071692</guid>
      <pubDate>Mon, 07 Dec 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[Venu® Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier owner, developer, and operator of luxury, experience-driven entertainment destinations. VENU's portfolio includes the award-winning Ford Amphitheater, Sunset Amphitheaters, Regent Bank Amphitheater, Phil Long Music Hall, The Hall at Bourbon Brothers, Bourbon Brothers Smokehouse and Tavern, Aikman Owners Clubs, and Roth's Sea & Steak, with venues operating and in development across Colorado, Georgia, Oklahoma, Tennessee, and Texas. The Company currently has six current projects representing approximately $1.5 billion in development, and was recently recognized by Forbes for its Luxe FireSuites® ownership model. VENU trades on NYSE American under the ticker VENU.]]></description>
    </item>
    <item>
      <title><![CDATA[BioVie]]></title>
      <link>https://www.redchip.com/webinar/BIVI/89396853693</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/BIVI/89396853693</guid>
      <pubDate>Tue, 08 Dec 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company’s lead drug candidate bezisterim inhibits the production of tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance – both of which are drivers of Alzheimer’s and Parkinson’s. Bezisterim is also being evaluated to treat the neurological symptoms associated with long COVID, which are associated with persistent systematic inflammation and neuroinflammation. In liver disease, the Company is actively exploring partnerships for a Phase 3 trial to evaluate BIV201 (continuous infusion terlipressin) to reduce further decompensation in participants with liver cirrhosis and ascites. BIV201 has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months.]]></description>
    </item>
    <item>
      <title><![CDATA[Mission Critical: Powering America's Defense and Industrial Renaissance]]></title>
      <link>https://www.redchip.com/webinar/redchip/83113241322</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/83113241322</guid>
      <pubDate>Wed, 09 Dec 2026 14:30:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Mission Critical: Powering America's Defense and Industrial Renaissance]]></title>
      <link>https://www.redchip.com/webinar/redchip/89902668668</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/89902668668</guid>
      <pubDate>Thu, 10 Dec 2026 14:30:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
  </channel>
</rss>
